SCHEMBL2638878

SCHEMBL2638878

Cc1cc(C)c2cccc(C(=O)c3c(Cl)ccc(S(=O)(=O)N4CCCC4C(=O)O)c3Cl)c2n1

nearest known ligand 0.56

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
RORC P51449 12/20 0.56
BDKRB2 P30411 2/20 0.47
BRD4 O60885 1/20 0.42
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560922 0.83 BDKRB2 (0.55) RORCBDKRB2
SCHEMBL2638880 0.82 RORC (0.55) RORCBDKRB2
SCHEMBL2344304 0.81 BDKRB2 (0.75) RORCBDKRB2
SCHEMBL3743960 0.81 RORC (0.83) RORCBDKRB2
SCHEMBL6946090 0.81 RORC (0.83) RORCBDKRB2
SCHEMBL8181772 0.76 RORC (0.71) RORCBDKRB2
SCHEMBL4592164 0.73 RORC (0.47) RORCBDKRB2
SCHEMBL7952802 0.73 RORC (0.72) RORCBDKRB2
SCHEMBL6946877 0.73 RORC (0.65) RORCBDKRB2
SCHEMBL6950221 0.72 RORC (1.00) RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303268-B1 PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE LUSO FARMACO INST (IT) 2012-06-20 EP claimed
JP-2011527296-A 2011-10-27 JP claimed
US-20100292156-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2010-11-18 US claimed
EP-2222275-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF Istituto Luso Farmaco d'Italia S.p.A. (IT) 2010-09-01 EP claimed
WO-2010003601-A1 PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE INSTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2010-01-14 WO claimed
WO-2009065507-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2009-05-28 WO claimed
US-20080221039-A1 Kinin Antagonists For Treating Bladder Dysfunction JERINI AG (DE) 2008-09-11 US claimed
EP-1901775-A2 KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION Jerini AG (DE) 2008-03-26 EP claimed
WO-2007003411-A2 KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION JERINI AG (DE) 2007-01-11 WO claimed
EP-1741444-A1 Kinin antagonists for treating bladder dysfunction Jerini AG (DE) 2007-01-10 EP claimed
US-9101627-B2 Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2015-08-11 US disclosed
EP-2303268-B1 PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE LUSO FARMACO INST (IT) 2012-06-20 EP disclosed
US-20100292156-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2010-11-18 US disclosed
EP-2222275-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF Istituto Luso Farmaco d'Italia S.p.A. (IT) 2010-09-01 EP disclosed
WO-2010003601-A1 PHARMACEUTICAL COMPOSITIONS BASED ON KININ B2 RECEPTOR ANTAGONISTS AND CORTICOSTEROIDS, AND THEIR USE INSTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2010-01-14 WO disclosed
WO-2009065507-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2009-05-28 WO disclosed
US-20080221039-A1 Kinin Antagonists For Treating Bladder Dysfunction JERINI AG (DE) 2008-09-11 US disclosed
EP-1901775-A2 KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION Jerini AG (DE) 2008-03-26 EP disclosed
WO-2007003411-A2 KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION JERINI AG (DE) 2007-01-11 WO disclosed
EP-1741444-A1 Kinin antagonists for treating bladder dysfunction Jerini AG (DE) 2007-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221039-A1 Kinin Antagonists For Treating Bladder Dysfunction BDKRB2, BDKRB1, F2R RORC 4878/4885BDKRB2 1/4885BRD4 1264/4885
US-20100292156-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING BRADYKININ ANTAGONISTS AND HYALURONIC ACID, AND USES THEREOF BDKRB2, BDKRB1, HCAR2 RORC 3493/4885BDKRB2 1/4885BRD4 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.